Semaglutide is a GLP-1 receptor agonist that is FDA approved for weight loss under the brand name Wegovy and for type 2 diabetes under the brand name Ozempic. Semaglutide is taken as a weekly subcutaneous injection.
Tirzepatide is a GLP-1 receptor agonist and GIP (glucose-dependent insulinotropic polypeptide) receptor. It is commonly known by the brand names Mounjaro for type 2 diabetes and Zepbound for weight loss.